- Home
- BLUE vs CUE Comparison
BLUE vs CUE Comparison
Compare BLUE & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLUE
- CUE
- Stock Information
- Founded
- BLUE 1992
- CUE 2014
- Country
- BLUE United States
- CUE United States
- Employees
- BLUE N/A
- CUE N/A
- Industry
- BLUE Biotechnology: Biological Products (No Diagnostic Substances)
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- BLUE Health Care
- CUE Health Care
- Exchange
- BLUE Nasdaq
- CUE Nasdaq
- Market Cap
- BLUE 82.2M
- CUE 77.3M
- IPO Year
- BLUE 2013
- CUE 2018
- Fundamental
- Price
- BLUE $8.14
- CUE $1.21
- Analyst Decision
- BLUE Hold
- CUE Strong Buy
- Analyst Count
- BLUE 9
- CUE 5
- Target Price
- BLUE $49.14
- CUE $5.00
- AVG Volume (30 Days)
- BLUE 292.7K
- CUE 389.8K
- Earning Date
- BLUE 11-14-2024
- CUE 03-10-2025
- Dividend Yield
- BLUE N/A
- CUE N/A
- EPS Growth
- BLUE N/A
- CUE N/A
- EPS
- BLUE N/A
- CUE N/A
- Revenue
- BLUE $53,120,000.00
- CUE $9,532,000.00
- Revenue This Year
- BLUE $145.88
- CUE $73.11
- Revenue Next Year
- BLUE $239.89
- CUE $11.02
- P/E Ratio
- BLUE N/A
- CUE N/A
- Revenue Growth
- BLUE 144.50
- CUE 149.53
- 52 Week Low
- BLUE $5.80
- CUE $0.45
- 52 Week High
- BLUE $38.40
- CUE $2.93
- Technical
- Relative Strength Index (RSI)
- BLUE 47.80
- CUE 48.27
- Support Level
- BLUE $7.96
- CUE $1.21
- Resistance Level
- BLUE $8.46
- CUE $1.75
- Average True Range (ATR)
- BLUE 0.68
- CUE 0.19
- MACD
- BLUE -0.06
- CUE -0.01
- Stochastic Oscillator
- BLUE 15.42
- CUE 32.50
About BLUE bluebird bio Inc.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.